Physician profile
Sayeh Moazami Lavasani
NPI 1205130572
$161,938.89
in general payments reported to CMS, 2019-2025
8 companies · $34K in 2025
The $34K reported for 2025 was more than what 92% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $9,015 · 2021: $19K · 2022: $1,651 · 2023: $24K · 2024: $49K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $79K · Consulting Fee: $13K · Travel and Lodging: $13K · Food and Beverage: $2,416 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $78,605.00 |
| Consulting Fee | $13,392.50 |
| Travel and Lodging | $12,678.33 |
| Food and Beverage | $2,416.38 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $44,665.99 | 2020-2023 | Tukysa |
| Astrazeneca Pharmaceuticals Lp | $39,951.17 | 2019-2025 | Enhertu, Datroway |
| Puma Biotechnology, INC. | $30,411.31 | 2019-2020 | |
| Pfizer INC. | $26,900.03 | 2024 | |
| Daiichi Sankyo INC. | $15,911.68 | 2022-2025 | Enhertu |
| Novartis Pharmaceuticals Corporation | $3,986.57 | 2021-2025 | |
| Amgen INC. | $61.51 | 2019 | |
| Gilead Sciences, INC. | $50.63 | 2021-2025 | Trodelvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sayeh Lavasani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.